SHU et syndromes de microangiopathie thrombotique apparentés : épidémiologie, physiopathologie et tableaux cliniques [Hemolytic and uremic syndrome and related thrombotic microangiopathies: Epidemiology, pathophysiology and clinics]. Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E. Rev Med Interne. 2017;38: 817-24.

Microangiopathies thrombotiques secondaires [Secondary thrombotic microangiopathies]. Coppo P; Centre de référence des microangiopathies thrombotiques (CNR-MAT). Rev Med Interne. 2017;38: 731-6.

The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope. Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, Lacroix-Desmazes S. Haematologica. 2017;102: 1833-41.

Management of thrombotic thrombocytopenic purpura. Coppo P; French Reference Center for Thrombotic Microangiopathies. Transfus Clin Biol. 2017 Sep;24(3):148-153.

Thrombotic thrombocytopenic purpura. Joly BS, Coppo P, Veyradier A. Blood 2017;129:2836-46.

Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, Gobert P, Wynckel A, Provôt F, Delmas Y, Mousson C, Servais A, Vrigneaud L, Veyradier A, Rondeau E, Coppo P; French Thrombotic Microangiopathies Reference Centre. PLoS One. 2017 May 18;12(5):e0177894.

Thrombotic microangiopathies and antineoplastic agents. Grangé S, Coppo P; Centre de référence des microangiopathies thrombotiques (CNR-MAT). Nephrol Ther. 2017 Apr;13 Suppl 1:S109-S113.

Thrombotic thrombocytopenic purpura. Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Nat Rev Dis Primers. 2017 Apr 6;3:17020.

Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Grall M, Azoulay E, Galicier L, Provôt F, Wynckel A, Poullin P, Grange S, Halimi JM, Lautrette A, Delmas Y, Presne C, Hamidou M, Girault S, Pène F, Perez P, Kanouni T, Seguin A, Mousson C, Chauveau D, Ojeda-Uribe M, Barbay V, Veyradier A, Coppo P, Benhamou Y.
Am J Hematol. 2017 Jan 30. doi: 10.1002/ajh.24665.

Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Joly BS, Vanhoorelbeke K, Veyradier A. Intensive Care Med. 2017 Jan 23. doi: 10.1007/s00134-016-4662-3.

Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Coppo P; French Reference Center for Thrombotic Microangiopathies. Transfus Apher Sci. 2016 Dec 30. pii: S1473-0502(16)30205-1.

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. J Thromb Haemost. 2017 Feb;15(2):312-322.